Compare Ares Capital Corporation (ARCC) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs BridgeBio Pharma Inc — how do they compare? Ares Capital Corporation trades at $20.03 (market cap $14.35B), while BridgeBio Pharma Inc trades at $83.86 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Ares Capital Corporation pays a 9.61% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ARCC | BBIO | |
|---|---|---|
Market Cap | $14.35B | $16.61B |
Sector | Financials | Health |
52-Week High | $22.68 | $90.17 |
52-Week Low | $17.45 | $47.29 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARCC trades at $20.01, up 1.99% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show Q2 2026 EPS of $0.47, slightly below the $0.4731 estimate, continuing a trend of minor misses. Revenue declined to $1.51B in 2025 from $1.7B in 2024, with net income margin at 81.77%. The stock offers a high dividend yield, with consistent payouts highlighted in recent news.
Outlook is mixed: strong analyst buy consensus (75%) and a stable dividend history support income investors, but declining revenue and tight dividend coverage pose risks. Price target consensus is $19.63, below the current price, suggesting limited upside. Macro risks in private credit, per WSJ on August 9, 2026, add caution.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
